All Articles

There does not exist a cookie-cutter approach to treating patients with cancer, due to a multitude of patient-related factors, such as gender, race, age, biomarkers, and comorbidities. Despite these factors, which may affect how individuals respond to specific therapeutic protocols, there are general guidelines, including those published by the National Comprehensive Cancer Network (NCCN),1 which can be used to help guide treatment practices to promote optimal clinical outcomes. Read More ›

The majority of leadership opportunities currently available in the medical practice community require individuals to be responsible for the operations of previously established businesses and teams. As a result, new and seasoned leaders alike are often finding themselves facing unique challenges as they navigate the nuances of assuming leadership of existing practices. This transition can be equally challenging for the staff members. In this article, we offer some strategies you can use to facilitate the process. Read More ›

According to results from a recent study, balstilimab, an investigational PD-1 inhibitor, demonstrated meaningful and durable clinical activity in patients with recurrent or metastatic cervical cancer. These findings were presented by Cailin E. Joyce, MD, Director, Applied Technology, Agenus, Boston, MA, during the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

It is estimated that in 2020, there were 6.3 million cases and 3.3 million deaths globally of mouth, pharynx, larynx, esophageal, colon, rectum, liver, and breast cancer. These cancers have causal links to alcohol consumption. However, patterns of alcohol use continue to change over time across the world. With changes in alcohol consumption and more recent cancer incidence data, new estimates of the alcohol-attributable burden of cancer are needed. Read More ›

Sacituzumab govitecan (Trodelvy), a Trop-2 antibody and topoisomerase inhibitor, showed promising results in a small clinical trial of patients with metastatic TNBC. These findings provided the basis for accelerated FDA approval of this agent in April 2020 for the treatment of patients with metastatic TNBC who have received ≥2 previous therapies in the metastatic setting, with full approval contingent on the results of the confirmatory phase 3 ASCENT study (Bardia A, et al. N Engl J Med. Read More ›

The advent of biologic drugs has had a significant impact on the management of patients with cancer. However, the high costs associated with these agents can hinder treatment access for many patients and place a significant burden on healthcare systems. As several biologics have come off patent over the past few years and more are expected to do so in the near future, biosimilars are poised to play an increasingly important role in reducing healthcare costs. Read More ›

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved pathologic complete response (pCR) rates versus chemotherapy alone in patients with resectable stage IB-IIIA non–small-cell lung cancer (NSCLC), according to final results from the CheckMate-816 clinical trial. Read More ›

Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. During the American Society of Clinical Oncology 2021 virtual annual meeting, Ferdinandos Skoulidis, MD, PhD, MRCP, Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, provided updated results from the phase 2 component of the CodeBreaK 100 clinical trial Read More ›

The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial. The findings were presented at the American Society of Clinical Oncology 2021 virtual annual meeting by lead investigator Giuseppe Curigliano, MD, PhD, Associate Professor, Medical Oncology, University of Milano, Italy. Read More ›

An Interview with Kelly Grosklags, LICSW, BCD, FAAGC Read More ›